These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28743036)

  • 1. RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.
    Massard C; Borget I; Farace F; Aspeslagh S; Le Deley MC; Le Tourneau C; Bidard FC; Pierga JY; Dieras V; Hofman P; Spano JP; Ferte C; Lacroix L; Soria JC
    Eur J Cancer; 2017 Sep; 83():185-193. PubMed ID: 28743036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Aggarwal C; Wang X; Ranganathan A; Torigian D; Troxel A; Evans T; Cohen RB; Vaidya B; Rao C; Connelly M; Vachani A; Langer C; Albelda S
    Lung Cancer; 2017 Oct; 112():118-125. PubMed ID: 29191584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.
    Olmos D; Baird RD; Yap TA; Massard C; Pope L; Sandhu SK; Attard G; Dukes J; Papadatos-Pastos D; Grainger P; Kaye SB; de Bono JS
    Clin Cancer Res; 2011 Aug; 17(15):5188-96. PubMed ID: 21531820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
    Thalgott M; Heck MM; Eiber M; Souvatzoglou M; Hatzichristodoulou G; Kehl V; Krause BJ; Rack B; Retz M; Gschwend JE; Andergassen U; Nawroth R
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1457-64. PubMed ID: 25708944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer.
    Okabe H; Tsunoda S; Hosogi H; Hisamori S; Tanaka E; Tanaka S; Sakai Y
    Ann Surg Oncol; 2015 Nov; 22(12):3954-61. PubMed ID: 25777087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
    Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
    J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer.
    Zhang Z; Xiao Y; Zhao J; Chen M; Xu Y; Zhong W; Xing J; Wang M
    Respirology; 2016 Apr; 21(3):519-25. PubMed ID: 26661896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
    Paoletti C; Li Y; Muñiz MC; Kidwell KM; Aung K; Thomas DG; Brown ME; Abramson VG; Irvin WJ; Lin NU; Liu MC; Nanda R; Nangia JR; Storniolo AM; Traina TA; Vaklavas C; Van Poznak CH; Wolff AC; Forero-Torres A; Hayes DF;
    Clin Cancer Res; 2015 Jun; 21(12):2771-9. PubMed ID: 25779948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
    Khoja L; Lorigan P; Zhou C; Lancashire M; Booth J; Cummings J; Califano R; Clack G; Hughes A; Dive C
    J Invest Dermatol; 2013 Jun; 133(6):1582-90. PubMed ID: 23223143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Circulating Tumour Cells on Production of IL-1α, IL-1β and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment.
    Vilsmaier T; Rack B; König A; Friese K; Janni W; Jeschke U; Weissenbacher T;
    Anticancer Res; 2016 Oct; 36(10):5227-5236. PubMed ID: 27798883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.
    Bork U; Rahbari NN; Schölch S; Reissfelder C; Kahlert C; Büchler MW; Weitz J; Koch M
    Br J Cancer; 2015 Apr; 112(8):1306-13. PubMed ID: 25867263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.